论文信息 - Preclinical Development Ridaforolimus ( AP 23573 ; MK-8669 ) , a Potent mTOR Inhibitor , Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens - 字舞流文

Preclinical Development Ridaforolimus ( AP 23573 ; MK-8669 ) , a Potent mTOR Inhibitor , Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

T. Clackson | L. Berk | V. Rivera | R. Pollock | N. Narasimhan | Frank Y Wang | J. Iuliucci | R. Squillace | Scott D. Wardwell | Y. Ning | David P Miller | Frank Y. Wang | David Miller